回盛生物拟使用不超过4000万元闲置募集资金进行现金管理

Core Viewpoint - Wuhan Huisheng Biotechnology Co., Ltd. has approved the use of up to 40 million yuan of idle raised funds for cash management, ensuring that the use of these funds does not affect the normal operation of the company and its fundraising projects [1][2] Group 1 - The board meeting was held on December 23, 2025, with all five directors present, and the resolution was deemed legally valid [1] - The cash management will allow for a rolling use of funds within the approved limit for a period of 12 months, with the requirement to return the funds to the designated account after maturity [1] - The company emphasizes that this cash management will not impact the progress of fundraising projects or the company's main business operations [1] Group 2 - The sponsor, CITIC Securities Co., Ltd., has issued a no-objection opinion, confirming that the cash management aligns with regulatory requirements and enhances fund efficiency without harming the interests of the company and its shareholders [2] - The resolution received unanimous approval from the board, with 5 votes in favor and none against [2] - Market analysts suggest that utilizing idle raised funds for cash management can improve financial returns while controlling risks, which is expected to have a positive impact on the company's short-term performance [2]